442 related articles for article (PubMed ID: 22718152)
1. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
Gomi F; Sawa M; Tsujikawa M; Nishida K
Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152
[TBL] [Abstract][Full Text] [Related]
2. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration.
Zweifel SA; Engelbert M; Khan S; Freund KB
Retina; 2009; 29(10):1527-31. PubMed ID: 19898185
[TBL] [Abstract][Full Text] [Related]
3. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study.
Flaxel C; Schain MB; Hamon SC; Francis PJ
Retina; 2012 Mar; 32(3):417-23. PubMed ID: 21862953
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
[TBL] [Abstract][Full Text] [Related]
5. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
[TBL] [Abstract][Full Text] [Related]
6. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
7. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
[TBL] [Abstract][Full Text] [Related]
9. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
[TBL] [Abstract][Full Text] [Related]
10. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
11. Multifocal pupillography identifies ranibizumab-induced changes in retinal function for exudative age-related macular degeneration.
Sabeti F; Maddess T; Essex RW; James AC
Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):253-60. PubMed ID: 22159011
[TBL] [Abstract][Full Text] [Related]
12. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
Park SS; Daftari I; Phillips T; Morse LS
Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
[TBL] [Abstract][Full Text] [Related]
13. Study on the potential benefit of adding topical bromfenac to intravitreal injections of ranibizumab for the therapy of exudative age-related macular degeneration.
Jonas JB; Libondi T
Retina; 2013 May; 33(5):1093. PubMed ID: 23446656
[No Abstract] [Full Text] [Related]
14. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
Zweifel SA; Saroj N; Shapiro H; Freund KB
Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
[TBL] [Abstract][Full Text] [Related]
15. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study.
Cohen SY; Mimoun G; Oubraham H; Zourdani A; Malbrel C; Queré S; Schneider V;
Retina; 2013 Mar; 33(3):474-81. PubMed ID: 23266880
[TBL] [Abstract][Full Text] [Related]
16. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration.
Rauch R; Weingessel B; Maca SM; Vecsei-Marlovits PV
Retina; 2012 Jul; 32(7):1260-4. PubMed ID: 22186738
[TBL] [Abstract][Full Text] [Related]
17. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration.
Lala C; Framme C; Wolf-Schnurrbusch UE; Wolf S
Acta Ophthalmol; 2013 Sep; 91(6):526-30. PubMed ID: 22697404
[TBL] [Abstract][Full Text] [Related]
18. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
Cho HJ; Kim CG; Yoo SJ; Cho SW; Lee DW; Kim JW; Lee JH
Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
[TBL] [Abstract][Full Text] [Related]
19. LuceDex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration.
Ranchod TM; Ray SK; Daniels SA; Leong CJ; Ting TD; Verne AZ
Retina; 2013 Sep; 33(8):1600-4. PubMed ID: 23549100
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]